TGF-β Signaling in Liver, Pancreas, and Gastrointestinal Diseases and Cancer
노바스템
2024-04-18
조회수 173
This comprehensive review explores the critical role of Transforming Growth Factor-beta (TGF-β) signaling in the pathogenesis and progression of gastrointestinal and hepatic diseases, including cancer. TGF-β is a key regulatory molecule influencing cellular growth, differentiation, and immune responses, often altered in cancer. Genetic mutations affecting the TGF-β signaling pathway are prevalent across various cancers, particularly those of the gastrointestinal tract, liver, and pancreas. The pathway, mediated by SMAD proteins, has dual roles, acting as a tumor suppressor in early stages and potentially facilitating cancer progression in later stages by modifying the tumor microenvironment. This dual nature highlights the complexity of targeting TGF-β in therapeutic strategies, as it involves not only the epithelial cells but also the immune and stromal components, which can shift the balance towards either suppression or enhancement of tumorigenesis.
The dual role of TGF-β in gastrointestinal and hepatic oncogenesis parallels the therapeutic approach of Novastem in utilizing stem cell therapies to modulate similar pathways for regeneration and anti-cancer effects. The ability of TGF-β to regulate immune and fibrotic responses can inform strategies to optimize Novastem’s stem cell therapies, potentially enhancing their efficacy in treating or preventing cancer by manipulating this pathway to maintain its tumor-suppressive activities while mitigating its tumor-promoting effects.
Regulation of Cell Fate and Immune Responses: TGF-β’s ability to direct cell differentiation and immune regulation underscores its potential as a therapeutic target, where its pathway modulation might replicate or enhance the regenerative effects seen in stem cell therapies.
Complex Role in Cancer Progression: Understanding the shifting roles of TGF-β from tumor suppressing to tumor promoting depending on the disease stage and cellular context is crucial for developing targeted therapies that can effectively intervene without exacerbating the disease.
Therapeutic Potential and Challenges: The complexity of the TGF-β signaling pathway presents both opportunities and challenges for developing effective treatments, necessitating careful consideration of when and how to target this pathway in cancer therapy.
This comprehensive review explores the critical role of Transforming Growth Factor-beta (TGF-β) signaling in the pathogenesis and progression of gastrointestinal and hepatic diseases, including cancer. TGF-β is a key regulatory molecule influencing cellular growth, differentiation, and immune responses, often altered in cancer. Genetic mutations affecting the TGF-β signaling pathway are prevalent across various cancers, particularly those of the gastrointestinal tract, liver, and pancreas. The pathway, mediated by SMAD proteins, has dual roles, acting as a tumor suppressor in early stages and potentially facilitating cancer progression in later stages by modifying the tumor microenvironment. This dual nature highlights the complexity of targeting TGF-β in therapeutic strategies, as it involves not only the epithelial cells but also the immune and stromal components, which can shift the balance towards either suppression or enhancement of tumorigenesis.
The dual role of TGF-β in gastrointestinal and hepatic oncogenesis parallels the therapeutic approach of Novastem in utilizing stem cell therapies to modulate similar pathways for regeneration and anti-cancer effects. The ability of TGF-β to regulate immune and fibrotic responses can inform strategies to optimize Novastem’s stem cell therapies, potentially enhancing their efficacy in treating or preventing cancer by manipulating this pathway to maintain its tumor-suppressive activities while mitigating its tumor-promoting effects.
#TGFbeta #CancerProgression #SMADSignaling #GastrointestinalCancer #LiverCancer #PancreaticCancer #StemCellTherapy #RegenerativeMedicine